Hereditary Angioedema in Women. Specific Challenges

Immunology and Allergy Clinics of North America

Volumn 33, Issue 4, 2013, Pages 505-511

  Bouillet, Laurence ^a   Gompel, Anne ^b,c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c National Reference Centre for Angioedema (CREAK)   (France)

Author keywords

Estrogen; Female; Hereditary angioedema; Progestin

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; GONADOTROPIN; GONADOTROPIN ANTAGONIST; ICATIBANT; LEVONORGESTREL; PROGESTERONE; STANOZOLOL; TAMOXIFEN; TRANEXAMIC ACID;

ACNE; ALOPECIA; AMENORRHEA; ANGIONEUROTIC EDEMA; BREAST ATROPHY; BREAST CANCER; CONTRACEPTION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG MEGADOSE; FEMALE; FERTILIZATION IN VITRO; HIRSUTISM; HUMAN; LOW DRUG DOSE; MENOPAUSE; MENSTRUAL IRREGULARITY; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; VIRILIZATION; WEIGHT GAIN; WOMEN'S HEALTH;

ESTROGEN; FEMALE; HEREDITARY ANGIOEDEMA; PROGESTIN;

ANDROGENS; ANGIOEDEMAS, HEREDITARY; BREAST NEOPLASMS; CONTRACEPTION; FEMALE; FERTILIZATION IN VITRO; HUMANS; MENOPAUSE; PHENOTYPE; PREGNANCY; SEX FACTORS;

EID: 84886718961     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.07.006     Document Type: Review

References (37)

1. Longhurst H., Cicardi M. Hereditary angio-oedema. Lancet 2012, 379:474-481.
2. Agostoni A., Cicardi M. Hereditary and acquired C1 inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992, 71:206-215.
3. Bork K., Meng G., Staubach P., et al. Hereditary angioedema: new findings concerning symptoms, affected organs and course. Am J Med 2006, 119:26-27.
4. Bouillet L, Launay D, Fain O, etal. Hereditary angioedema with C1inh deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol, in press.
5. Bouillet L., Longhurst H., Boccon-Gibod I., et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008, 11:484.e1-484.e4.
6. Yip J., Cunliffe W.J. Hormonally exacerbated hereditary angioedema. Australas J Dermatol 1992, 33:35-38.
7. Bork K., Fischer B., Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003, 114:294-298.
8. Borradori L., Marie O., Ryboad M., et al. Hereditary angioedema and oral contraception. Dermatologica 1990, 181:78-79.
9. McGlinchey P.G., McCluskey D.R. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 2000, 320:212-213.
10. Saule C., Boccon-Gibod I., Fain O., et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy 2013, 43:475-482.
11. Visy B., Füst G., Varga L., et al. Sex hormones in hereditary angioneurotic edema. Clin Endocrinol (Oxf) 2004, 60:508-515.
12. Madeddu P., Emanueli C., Song Q., et al. Regulation of bradykinin B2 receptor expression by oestrogen. Br J Pharmacol 1997, 121:1763-1791.
13. Gordon E.M., Douglas J.G., Ratnoff O.D., et al. The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomised rats. Blood 1985, 66:602-605.
14. Norris L.A., Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 1996, 103:261-267.
15. Gordon E.M., Ratnoff O.D., Saito H., et al. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. JLab Clin Med 1980, 96:762-769.
16. Teede H.J., McGrath B.P., Smolich J.J., et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000, 20:1404-1409.
17. Nogawa N., Sumino H., Ichikawa S., et al. Effect of long term hormone replacement therapy on angiotensin converting enzyme activity and bradykinin in post menopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001, 8:210-215.
18. Bork K., Wulff K., Hardt J., et al. Hereditary angiodema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. JAllergy Clin Immunol 2009, 124:129-134.
19. Vitrat-Hincky V., Gompel A., Dumestre-Perard C., et al. Type III Hereditary angiooedema: clinical and biological features in a French cohort. Allergy 2010, 65:1331-1336.
20. Bork K., Barnstedt S.E., Koch P., et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000, 356:213-217. 27.
21. Binkley K.E., Davis A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. JAllergy Clin Immunol 2000, 106:546-550.
22. Martin L., Degenne D., Toutain A., et al. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. JAllergy Clin Immunol 2001, 107:747-748.
23. Martin L., Raison-Peyron N., Nöthen M.M., et al. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. JAllergy Clin Immunol 2007, 120:975-977.
24. Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol 2010, 6:17-20.
25. Martinez-Saguer I., Rusicke E., Aygören-Pürsün E., et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010, 203:131.e1-131.e7.
26. Czaller I., Visy B., Csuka D., et al. The natural history of hereditary angioedema and the impact of treatment with human C1- inhibitor concentrate during pregnancy: a long term survey. Eur J Obstet Gynecol Reprod Biol 2010, 152:44-49.
27. Picone O., Donnadieu A.C., Brivet F., et al. Obstetrical complications and outcome in two families with hereditary angioedema due to mutation in the F12 gene. Obstet Gynecol Int 2010, 2010:957507.
28. Caballero T., Farkas H., Bouillet L., et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. JAllergy Clin Immunol 2012, 129:308-320.
29. Bouillet L., Ponard D., Rousset H., et al. Acase of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007, 156:1063-1065.
30. Lindoff C., Rybo G., Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993, 70:238-240.
31. Baker J.W., Craig T.J., Riedl M.A., et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc 2013, 34:162-169.
32. Farkas H., Csuka D., Tóth F., et al. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. Eur J Obstet Gynecol Reprod Biol 2012, 165:366-367.
33. Rousset-Jablonski C., Thalabard J.C., Gompel A. Tamoxifen contraindicated in women with hereditary angioedema?. Ann Oncol 2009, 20:1281-1282.
34. Gelfand J.A., Sherins R.J., Alling D.W., et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. NEngl J Med 1976, 295:1444-1448.
35. Cicardi M., Castelli R., Zingale L.C., et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. JAllergy Clin Immunol 1997, 99:194-196.
36. Zurlo J.J., Frank M.M. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990, 54:64-72.
37. Cicardi M., Bergamaschini L., Cugno M., et al. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. JAllergy Clin Immunol 1991, 87:768-773.